A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.

Robinson T, Escara-Wilke J, Dai J, Zimmermann J, Keller ET

The Prostate27 May 2023Cited by 12 (Europe PMC)

PMID37244751PMCIDPMC10576997DOI10.1002/pros.24584PepBankPUB-37244751

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with prostate cancer bone metastases, adding balixafortide reduced tumor burden versus docetaxel alone.
In plain wordsIn mice with prostate cancer bone metastases, adding balixafortide reduced tumor burden more than docetaxel alone.
Peptide
Balixafortide
Outcome
DecreaseTumor burden
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
docetaxel alone
Outcome group
Tumor growth · Cancer
Studied dose
20 mg/kg twice daily · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Tumor burden was lower in the combo group compared to the DOC alone group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
Report a problemFND-3724475101
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with prostate cancer bone metastases, adding balixafortide did not lower lesion area versus docetaxel alone.
In plain wordsIn mice with prostate cancer bone metastases, adding balixafortide did not lower bone lesion area versus docetaxel alone.
Peptide
Balixafortide
Outcome
No significant changeOsteolytic lesion area
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
docetaxel alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mg/kg twice daily · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Treatment with the combination had no impact on the number of mice with osteolytic lesions, however the area of osteolytic lesions was lower in the combo group compared to the vehicle and BLX groups, but not the DOC group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
Report a problemFND-3724475105
03AnimalAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, adding balixafortide did not lower serum TRAcP versus docetaxel alone.
In plain wordsIn mice with prostate cancer bone metastases, adding balixafortide did not lower blood TRAcP versus docetaxel alone.
Peptide
Balixafortide
Outcome
No significant changeSerum TRAcP
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
docetaxel alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mg/kg twice daily · subcutaneousAs given in this study (mouse).
Source sentences
Summary
Serum TRAcP levels were lower in the combo compared to vehicle group, but not the other groups.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
Report a problemFND-3724475107
04AnimalAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, cleaved caspase-3 staining was highest with balixafortide alone.
In plain wordsIn mice with prostate cancer bone metastases, cleaved caspase-3 staining was highest with balixafortide alone.
Peptide
Balixafortide
Outcome
IncreaseCleaved caspase-3 in balixafortide arm
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
other treatment groups
Outcome group
Tumor growth · Cancer
Studied dose
20 mg/kg twice daily · subcutaneousAs given in this study (mouse).
Source sentences
Summary
whereas, cleaved caspase-3 staining was lowest in the Combo group and highest in the BLX group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
Report a problemFND-3724475109
05AnimalAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, adding balixafortide increased IFNγ versus docetaxel alone.
In plain wordsIn mice with prostate cancer bone metastases, adding balixafortide increased IFNγ more than docetaxel alone.
Peptide
Balixafortide
Outcome
IncreaseIFNγ
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
docetaxel alone
Outcome group
Immune response · Immune and inflammation
Studied dose
20 mg/kg twice daily · subcutaneousAs given in this study (mouse).
Source sentences
Summary
There was no difference between the treatment groups for IL-2, but the combo group had increased levels of IFNγ compared to the DOC group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
Report a problemFND-3724475113

Studies that did not test the peptide alone8

In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Balixafortide.

06AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome
In mice with prostate cancer bone metastases, docetaxel plus balixafortide did not affect numbers with osteolytic lesions.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide did not affect numbers with bone-destroying lesions.
Peptide
Balixafortide
Outcome
No significant changeNumber with osteolytic lesions
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Treatment with the combination had no impact on the number of mice with osteolytic lesions, however the area of osteolytic lesions was lower in the combo group compared to the vehicle and BLX groups, but not the DOC group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475102
07AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome
In mice with prostate cancer bone metastases, docetaxel plus balixafortide reduced osteolytic lesion area versus vehicle.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide reduced bone lesion area versus vehicle.
Peptide
Balixafortide
Outcome
DecreaseOsteolytic lesion area
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Treatment with the combination had no impact on the number of mice with osteolytic lesions, however the area of osteolytic lesions was lower in the combo group compared to the vehicle and BLX groups, but not the DOC group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475103
08AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Efficacy outcome
In mice with prostate cancer bone metastases, docetaxel plus balixafortide reduced osteolytic lesion area versus balixafortide alone.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide reduced bone lesion area more than balixafortide alone.
Peptide
Balixafortide
Outcome
DecreaseOsteolytic lesion area
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
balixafortide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Treatment with the combination had no impact on the number of mice with osteolytic lesions, however the area of osteolytic lesions was lower in the combo group compared to the vehicle and BLX groups, but not the DOC group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475104
09AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, docetaxel plus balixafortide lowered serum TRAcP versus vehicle.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide lowered blood TRAcP versus vehicle.
Peptide
Balixafortide
Outcome
DecreaseSerum TRAcP
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum TRAcP levels were lower in the combo compared to vehicle group, but not the other groups.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475106
10AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, docetaxel plus balixafortide did not lower serum TRAcP versus balixafortide alone.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide did not lower blood TRAcP versus balixafortide alone.
Peptide
Balixafortide
Outcome
No significant changeSerum TRAcP
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
balixafortide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum TRAcP levels were lower in the combo compared to vehicle group, but not the other groups.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475108
11AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, cleaved caspase-3 staining was lowest with docetaxel plus balixafortide.
In plain wordsIn mice with prostate cancer bone metastases, cleaved caspase-3 staining was lowest with docetaxel plus balixafortide.
Peptide
Balixafortide
Outcome
DecreaseCleaved caspase-3 in combination arm
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
other treatment groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
whereas, cleaved caspase-3 staining was lowest in the Combo group and highest in the BLX group.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475110
12AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, docetaxel plus balixafortide increased CD34-positive microvessels versus control.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide increased CD34-positive microvessels versus control.
Peptide
Balixafortide
Outcome
IncreaseCD34-positive microvessels
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
control
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The DOC and combo groups had more CD34+ microvessels than the control and BLX groups.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475111
13AnimalNot a test of Balixafortide aloneAnimal study (in vivo)Activity measurement
In mice with prostate cancer bone metastases, docetaxel plus balixafortide increased CD34-positive microvessels versus balixafortide alone.
In plain wordsIn mice with prostate cancer bone metastases, docetaxel plus balixafortide increased CD34-positive microvessels versus balixafortide alone.
Peptide
Balixafortide
Outcome
IncreaseCD34-positive microvessels
Study
mousen: not reported in source
PC-3 tibial prostate cancer bone metastases
Comparator
balixafortide alone
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The DOC and combo groups had more CD34+ microvessels than the control and BLX groups.
2 context sentences(design, population, supporting numbers)
Summary · context
PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases.
Summary · context
Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX).
In this study, Balixafortide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Balixafortide.
Report a problemFND-3724475112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.